Overview

Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen

Status:
Withdrawn
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if intrathecal administration of baclofen can reduce symptoms of severe tactile defensiveness and autism spectrum disorder.
Phase:
N/A
Details
Lead Sponsor:
University of Missouri-Columbia
Treatments:
Baclofen